Selection of currently ongoing clinical pharmaceutical trials at the NCRC

Multiple Sclerosis studies / MOGAD:

Title

Link to the public  register

Recruitment
status

A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis (HERCULES)

NCT04411641 finished
A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive  multiple sclerosis (PERSEUS)

NCT04458051 active
A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab as monotherapy or in addition to baseline therapy in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)

NCT05271409 active

A Randomized, double-blind, Placebo-controlled, multicenter Phase 3 pivotal study to evaluate the efficacy and safety of rozanolixizumab to treat adult patients with Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD)

NCT05063162 active

 

Myasthenia gravis studies:

Titel

Link to the public register

Recruitment
status

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized
Myasthenia Gravis 

NCT03920293 active
Evaluating the Long-Term Safety and Tolerability of Efgartigimod
PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis (ADAPTSC+)

NCT04818671 active
Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis 

NCT04951622 active
A Phase 3B, Randomized, Open-label, Parallel-Group Trial to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis (ADAPT NXT)

NCT04980495 active
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Generalized Myasthenia Gravis

NCT05218096 active
A Phase 3, multinational, randomized, double-blind, placebo-controlled trial to examine the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Symptomatic Generalized Myasthenia Gravis (NIMBLE)  NCT05070858 active 

 

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) studies:

Title

Link to the public register 

Recruitment
status

A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (ADHERE)

NCT04281472 active
Gamunex® 10% Use in Patients with Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP) or Multifocal Motor Neuropathy (MMN) in clinical Routine:
 Observational study to assess Individualized Treatment
Decisions (I-GUIDE)
Sponsor-Reg.
GPN-001
active

 

Autoimmune encephalitis studies:

Title

Link to the public register

Rekruitment
status

A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis (AIE001)

NCT04875975 active